Skip to content

ResMed RMD EV / EBITDA

EV / EBITDA at other companies

Eli Lilly logo
Eli LillyLLY
25.9×-24.4×
Stryker logo
StrykerSYK
22.1×-11.8×
GE HealthCare Technologies logo
GE HealthCare TechnologiesGEHC
13.3×-0.8×
Boston Scientific logo
Boston ScientificBSX
28.3×-8.5×
Intuitive Surgical logo
Intuitive SurgicalISRG
77.8×+12.8×
Abbott logo
AbbottABT
18.9×-4.1×

Other financials

Income statement

See full
Revenue$1.4B+10.8%
Gross profit$891.0M+16.3%
Operating income$499.8M+17.3%
Net income$398.7M+9.2%
EPS (diluted)$2.74+10.5%

Balance sheet

See full
Cash & equivalents$1.7B+78.0%
Total debt$1.1B+29.8%
Total equity$6.5B+17.1%
Total assets$8.8B+16.1%

Cash flow

See full
Operating cash flow$554.1M-4.2%
CapEx$33.7M+61.8%
Free cash flow$520.5M-6.7%

Valuation

See full
Market cap$27.36B-0.5%
Enterprise value$26.8B-2.0%
P/E18×-2.9×
P/S4.9×-0.5×

Profitability

See full
Gross margin61.6%+2.8pp
Operating margin34.2%+2.1pp
Net margin27.4%+1.3pp

Returns & leverage

See full
Return on equity25.2%-0.6pp
Debt / equity0.2×0.0×
Current ratio-0.4×

Where this comes from

Calculated from ResMed’s reported figures.

Based on the most recent quarter.

The official record: ResMed’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →

Ask your AI about ResMed's ev / ebitda.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is ResMed's EV / EBITDA?
ResMed (RMD) reported EV / EBITDA of 15.2× in Q1 2026.
How has ResMed's EV / EBITDA changed year-over-year?
ResMed's EV / EBITDA decreased by 16.9% year-over-year, from 18.3× to 15.2×.
What is the long-term trend for ResMed's EV / EBITDA?
Over 4 years (2021 to 2025), ResMed's EV / EBITDA has grown at a -9.2% compound annual growth rate (CAGR), from 118.1× to 80.3×.
What does EV / EBITDA mean?
What the whole business (debt included) costs relative to its operating cash earnings.
How do you interpret EV / EBITDA?
Lets you compare companies with different leverage and tax positions on a like-for-like basis — the standard multiple in M&A. Lower can mean cheaper, subject to growth and capital intensity.
How does EV / EBITDA compare across companies?
Broadly comparable across non-financial sectors; not used for banks and insurers, where EBITDA is not meaningful.